- Home
- CLSK vs ARWR Comparison
CLSK vs ARWR Comparison
Compare CLSK & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- ARWR
- Stock Information
- Founded
- CLSK 1987
- ARWR 2003
- Country
- CLSK United States
- ARWR United States
- Employees
- CLSK N/A
- ARWR N/A
- Industry
- CLSK Finance: Consumer Services
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- ARWR Health Care
- Exchange
- CLSK Nasdaq
- ARWR Nasdaq
- Market Cap
- CLSK 2.8B
- ARWR 2.6B
- IPO Year
- CLSK N/A
- ARWR 1993
- Fundamental
- Price
- CLSK $10.87
- ARWR $20.20
- Analyst Decision
- CLSK Strong Buy
- ARWR Buy
- Analyst Count
- CLSK 8
- ARWR 11
- Target Price
- CLSK $22.71
- ARWR $43.33
- AVG Volume (30 Days)
- CLSK 23.6M
- ARWR 2.7M
- Earning Date
- CLSK 02-06-2025
- ARWR 02-10-2025
- Dividend Yield
- CLSK N/A
- ARWR N/A
- EPS Growth
- CLSK N/A
- ARWR N/A
- EPS
- CLSK N/A
- ARWR N/A
- Revenue
- CLSK $378,968,000.00
- ARWR $3,551,000.00
- Revenue This Year
- CLSK $143.22
- ARWR $3,402.96
- Revenue Next Year
- CLSK $29.76
- ARWR $123.96
- P/E Ratio
- CLSK N/A
- ARWR N/A
- Revenue Growth
- CLSK 125.03
- ARWR N/A
- 52 Week Low
- CLSK $7.64
- ARWR $17.05
- 52 Week High
- CLSK $24.72
- ARWR $36.72
- Technical
- Relative Strength Index (RSI)
- CLSK 49.43
- ARWR 51.11
- Support Level
- CLSK $9.57
- ARWR $18.55
- Resistance Level
- CLSK $11.08
- ARWR $20.65
- Average True Range (ATR)
- CLSK 0.83
- ARWR 0.94
- MACD
- CLSK 0.06
- ARWR 0.05
- Stochastic Oscillator
- CLSK 45.94
- ARWR 51.78
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.